N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST) is the
sulfotransferase responsible for biosynthesis of highly sulfated
chondroitin sulfate CS-E. Although involvements of CS-E in neuronal cell functions have been extensively analyzed, the role of
GalNAc4S-6ST in astrocytic
tumor progression remains unknown. Here, we reveal that
GalNAc4S-6ST transcripts were detected in astrocytic
tumors derived from all 30 patients examined using quantitative reverse transcription-PCR analysis. Patients with high
GalNAc4S-6ST mRNA expression had significantly worse outcome compared with patients with low expression, and multivariate survival analysis disclosed that
GalNAc4S-6ST is an independent poor prognostic factor for astrocytic
tumors. We then tested whether CS-E enhanced haptotaxic migration of
glioblastoma U251-MG cells that endogenously express both the CS-E's scaffold
tyrosine phosphatase ζ (PTPζ) and
GalNAc4S-6ST, in the presence of CS-E's preferred
ligands,
pleiotrophin (PTN) or
midkine (MK), using a modified Boyden chamber method. Haptotaxic stimulation of cell migration by PTN was most robust on control
siRNA-transfected U251-MG cells, while that enhancing effect was cancelled following transduction of
GalNAc4S-6ST siRNA. Similar results were obtained using MK, suggesting that both PTN and MK enhance migration of U251-MG cells by binding to CS-E. We also found that PTPζ as well as PTN and MK were frequently expressed in astrocytic
tumor cells. Thus, our findings indicate that
GalNAc4S-6ST mRNA expressed by astrocytic
tumor cells is associated with poor patient prognosis likely by enhancing CS-E-mediated
tumor cell motility in the presence of PTN and/or MK.